Viatris Inc. filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission on November 5, 2026, covering the fiscal quarter ended September 30, 2026.
Key Highlights
- Shares outstanding: As of November 2, 2026, Viatris reported 1,146,454,729 shares of common stock outstanding, par value $0.01 per share.
- Large accelerated filer: The company indicated it qualifies as a large accelerated filer under Rule 12b-2 of the Exchange Act.
- Revolving credit facility: The company references a $3.5 billion revolving facility dated September 27, 2024, with Bank of America, N.A. as administrative agent.
- Commercial Paper Program: The company maintains a $1.65 billion unsecured commercial paper program entered into as of November 16, 2020.
- Idorsia Transaction: According to the filing, Viatris acquired development programs from Idorsia Pharmaceuticals Ltd. for an upfront payment of $350 million, plus potential milestone and royalty payments.
- OTC Business divestiture: The filing references that Viatris divested its OTC business to Cooper Consumer Health SAS in July 2024, including two manufacturing sites in France and Italy and an R&D site in Monza, Italy.
Viatris Files Third-Quarter 2026 Report Covering Operations Across Four Business Segments
Viatris Inc. (NASDAQ:VTRS), headquartered at 1000 Mylan Boulevard, Canonsburg, Pennsylvania, filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 5, 2026. The filing identifies four reportable business segments: Developed Markets, Emerging Markets, Greater China, and JANZ (Japan, Australia and New Zealand), according to the filing's glossary of defined terms.
The company disclosed that 1,146,454,729 shares of common stock were outstanding as of November 2, 2026. The filing also confirms Viatris is not a shell company and has met all required electronic filing obligations under Rule 405 of Regulation S-T during the preceding 12 months, as indicated by the registrant's check-mark responses on the cover page.
Among the key financial structures referenced in the filing's definitions section, Viatris maintains a $3.5 billion revolving credit facility and a $1.65 billion unsecured Commercial Paper Program. The filing also references the 2033 Euro Senior Notes, described as 4.250% Senior Notes due 2033 issued by Viatris Inc., fully and unconditionally guaranteed on a senior unsecured basis by Mylan Inc., Mylan II B.V. and Utah Acquisition Sub Inc. The company further discloses the Idorsia Transaction, under which Viatris acquired development programs for selatogrel and cenerimod for an upfront payment of $350 million, with additional potential development, regulatory, and sales milestone payments, as well as potential tiered sales royalties, according to the filing.
What Was Disclosed
Viatris Inc. submitted its Form 10-Q for the quarter ended September 30, 2026, disclosing 1,146,454,729 shares outstanding as of November 2, 2026, its four operating segments, key debt facilities, and the terms of its Idorsia asset acquisition.




Please wait processing your request...